Market Research Logo

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2015

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2015’, provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview
Therapeutics Development
Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview
Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Investigation by Universities/Institutes
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Investigation by Universities/Institutes
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development
AstraZeneca PLC
Athersys, Inc.
Bayer AG
Betagenon AB
Cardiolynx AG
CardioVascular BioTherapeutics, Inc.
Celgene Corporation
Diffusion Pharmaceuticals LLC
DNAVEC Corporation
KunWha Pharmaceutical Co., Ltd.
MedImmune, LLC
miRagen Therapeutics, Inc.
Multi Gene Vascular Systems Ltd
Nuo Therapeutics, Inc.
Proteon Therapeutics, Inc.
Recardio GmbH
RegenoCELL Therapeutics, Inc.
Resverlogix Corp.
Sagene Pharmaceuticals, Inc.
Stemedica Cell Technologies, Inc.
Theravasc, Inc.
ViroMed Co., Ltd.
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(cilostazol + organic nitrate) ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AEM-28 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALD-301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Annexin A-5 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CVBT-141C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DVC1-0101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ELS-140 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEDI-6012 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mesenchymal Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGN-6114 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MultiGeneAngio - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MultiGeneGraft - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MultiStem - Drug Profile
Product Description
Mechanism of Action
R&D Progress
O-304 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PDA-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REC-03 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rivaroxaban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RVX-208 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sarpogrelate SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selegiline + Antiplatelet Drugs - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sodium nitrite SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SYN-20112312RU - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ticagrelor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
transcrocetinate sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TXA-127 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VM-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vonapanitase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Recent Pipeline Updates
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones
Featured News & Press Releases
Feb 02, 2015: The Small molecule AMPK activator O304 acts as an oral PCSK9 inhibitor
Jan 08, 2015: Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease
Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals
Jul 09, 2014: Development Of Russian Innovative Drug For Peripheral Arterial Disease Is Supported By The Council Of Maryland Biotech Companies (USA)
Mar 17, 2014: AstraZeneca Announces Progress on Global PARTHENON Clinical Trial Program with BRILINTA in High-Risk Cardiovascular Disease Patient Populations in Advance of American College of Cardiology Scientific Session
Mar 05, 2013: Tarix Pharma's Peptide Technology Stimulates Revascularization Following Ischemia
Dec 06, 2012: Cytomedix Announces Landmark Bright Cell Therapy Study In Peripheral Arterial Disease
Oct 15, 2012: Proteon Therapeutics Initiates Patient Enrollment In Phase I Clinical Study Of PRT-201 In Patients Suffering From Peripheral Artery Disease
Jul 17, 2012: AstraZeneca To Initiate New Study Of BRILINTA In Patients With Peripheral Artery Disease
Nov 15, 2010: Diffusion Achieves Positive Results In Phase I/II Clinical Trial Of Trans Sodium Crocetinate In Peripheral Artery Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2015
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AstraZeneca PLC, H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athersys, Inc., H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Bayer AG, H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Betagenon AB, H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Cardiolynx AG, H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Celgene Corporation, H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Diffusion Pharmaceuticals LLC, H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by DNAVEC Corporation, H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by KunWha Pharmaceutical Co., Ltd., H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by MedImmune, LLC, H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by miRagen Therapeutics, Inc., H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Multi Gene Vascular Systems Ltd, H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Nuo Therapeutics, Inc., H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Proteon Therapeutics, Inc., H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Recardio GmbH, H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by RegenoCELL Therapeutics, Inc., H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Resverlogix Corp., H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Sagene Pharmaceuticals, Inc., H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Stemedica Cell Technologies, Inc., H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Theravasc, Inc., H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ViroMed Co., Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics - Recent Pipeline Updates, H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..1), H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..2), H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..3), H1 2015
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2015
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report